160 related articles for article (PubMed ID: 19455462)
1. Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.
Sadek I; Dispenzieri A; Gertz MA; Kumar S
Leuk Lymphoma; 2009 Jun; 50(6):1033-5. PubMed ID: 19455462
[No Abstract] [Full Text] [Related]
2. Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
Laura R; Cibeira MT; Uriburu C; Yantorno S; Salamero O; Bladé J; Montserrat E
Eur J Haematol; 2006 May; 76(5):405-8. PubMed ID: 16529604
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Adams J; Kauffman M; Esseltine DL; Schenkein DP; Anderson KC
Br J Haematol; 2004 Oct; 127(2):165-72. PubMed ID: 15461622
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of bortezomib in relapsed multiple myeloma.
Jagannath S
Clin Adv Hematol Oncol; 2006 May; 4(5):2-3; discussion 8; suppl 13. PubMed ID: 16830423
[No Abstract] [Full Text] [Related]
5. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib for multiple myeloma.
Popat R; Joel S; Oakervee H; Cavenagh J
Expert Opin Pharmacother; 2006 Jul; 7(10):1337-46. PubMed ID: 16805719
[TBL] [Abstract][Full Text] [Related]
7. RAS mutation status and bortezomib therapy for relapsed multiple myeloma.
Smith D; Armenteros E; Percy L; Kumar M; Lach A; Herledan G; Stubbs M; Downward J; Yong K
Br J Haematol; 2015 Jun; 169(6):905-8. PubMed ID: 25580780
[No Abstract] [Full Text] [Related]
8. [Use of proteasome inhibitors in the treatment of patients with multiple myeloma].
Rukavitsyn OA
Ter Arkh; 2006; 78(10):40-4. PubMed ID: 17180936
[No Abstract] [Full Text] [Related]
9. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Jagannath S; Barlogie B; Berenson JR; Singhal S; Alexanian R; Srkalovic G; Orlowski RZ; Richardson PG; Anderson J; Nix D; Esseltine DL; Anderson KC;
Cancer; 2005 Mar; 103(6):1195-200. PubMed ID: 15690325
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitor for treatment of multiple myeloma.
Ahmad K
Lancet Oncol; 2005 Aug; 6(8):546. PubMed ID: 16094754
[No Abstract] [Full Text] [Related]
12. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone.
Davies FE; Wu P; Jenner M; Srikanth M; Saso R; Morgan GJ
Haematologica; 2007 Aug; 92(8):1149-50. PubMed ID: 17650451
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Caballero-Velázquez T; López-Corral L; Encinas C; Castilla-Llorente C; Martino R; Rosiñol L; Sampol A; Caballero D; Serrano D; Heras I; San Miguel J; Pérez-Simón JA
Br J Haematol; 2013 Aug; 162(4):474-82. PubMed ID: 23772672
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib in multiple myeloma.
Faix JD
N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14507954
[No Abstract] [Full Text] [Related]
16. Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma.
Hsiao SC; Wang MC; Chang H; Pei SN
Ann Pharmacother; 2010 Mar; 44(3):587-9. PubMed ID: 20150504
[TBL] [Abstract][Full Text] [Related]
17. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Niesvizky R; Richardson PG; Rajkumar SV; Coleman M; Rosiñol L; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Boral AL; Esseltine DL; Anderson KC; Bladé J
Br J Haematol; 2008 Oct; 143(1):46-53. PubMed ID: 18673366
[TBL] [Abstract][Full Text] [Related]
18. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
Fröhlich K; Holle JU; Aries PM; Gross WL; Moosig F
Ann Rheum Dis; 2011 Jul; 70(7):1344-5. PubMed ID: 21173019
[No Abstract] [Full Text] [Related]
19. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
Jagannath S; Barlogie B; Berenson JR; Siegel DS; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Esseltine DL; Anderson KC
Br J Haematol; 2008 Nov; 143(4):537-40. PubMed ID: 18783399
[TBL] [Abstract][Full Text] [Related]
20. Position statement on the use of bortezomib in multiple myeloma.
Morgan GJ; Davies FE; Cavenagh JD; Jackson GH; ;
Int J Lab Hematol; 2008 Feb; 30(1):1-10. PubMed ID: 18190461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
